Celyad in Institut Curie collaboration to develop its immuno-oncology program

22 March 2016

Belgian biotech firm Celyad (Euronext Brussels: CYAD) has announced a strategic partnership with the Institut Curie’s Inserm Cancer and Immunity Unit to further develop its NKR-T pipeline in cellular immunotherapies for cancer.

Celyad is a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology. It has called academic research collaborations “integral to bringing Celyad science and product candidates to patients and their families”.

In this partnership, the company and Institut Curie will pool their expertise to progress Celyad immuno-oncology pipeline, aimed at bringing novel cellular immunotherapies to cancer patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK